Loe Taylor K, Lazzerini Denchi Eros, Tricola Gianna M, Azeroglu Benura
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, U.S.A.
Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD 20892, U.S.A.
Biochem Soc Trans. 2023 Oct 31;51(5):1935-1946. doi: 10.1042/BST20230265.
Approximately 15% of human cancers depend on the alternative lengthening of telomeres (ALT) pathway to maintain telomeres and proliferate. Telomeres that are elongated using ALT display unique features raising the exciting prospect of tailored cancer therapies. ALT-mediated telomere elongation shares several features with recombination-based DNA repair. Strikingly, cells that use the ALT pathway display abnormal levels of replication stress at telomeres and accumulate abundant extrachromosomal telomeric DNA. In this review, we examine recent findings that shed light on the ALT mechanisms and the strategies currently available to suppress this telomere elongation mechanism.
约15%的人类癌症依赖端粒替代延长(ALT)途径来维持端粒并实现增殖。通过ALT延长的端粒具有独特特征,为定制化癌症治疗带来了令人兴奋的前景。ALT介导的端粒延长与基于重组的DNA修复有几个共同特征。引人注目的是,使用ALT途径的细胞在端粒处表现出异常水平的复制应激,并积累大量的染色体外端粒DNA。在这篇综述中,我们研究了最近的发现,这些发现揭示了ALT机制以及目前可用于抑制这种端粒延长机制的策略。